Shanthi Viswanathan1, Anna H Y Wong2, Amy M L Quek3, Nobuhiro Yuki4. 1. Department of Neurology, Kuala Lumpur Hospital, Malaysia. Electronic address: shivenda70@yahoo.com. 2. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: mdcwhyi@nus.edu.sg. 3. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: Amy_QUEK@nuhs.edu.sg. 4. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: mdcyuki@nus.edu.sg.
Abstract
OBJECTIVES: To evaluate the use of intravenous immunoglobulin (IVIG) in preventing relapses in patients with neuromyelitis optica (NMO) and its spectrum disorders (NMOSDs). METHODS: Six NMO/NMOSD patients who were treated with IVIG induction dose followed by 2- to 3- monthly infusions were retrospectively identified. Annualized relapse rates (ARR) and Expanded Disability Status Scale (EDSS) pre- and post-IVIG were recorded. RESULTS: Median number of relapses and median ARR significantly reduced from 8.0 to 1.0 and 0.75 to 0.15 (p<0.05) respectively. Median EDSS of 6.5 remained the same. Median duration of treatment was 4.0 years. CONCLUSION: IVIG may be used to reduce the relapse frequency in patients with NMO/NMOSD.
OBJECTIVES: To evaluate the use of intravenous immunoglobulin (IVIG) in preventing relapses in patients with neuromyelitis optica (NMO) and its spectrum disorders (NMOSDs). METHODS: Six NMO/NMOSD patients who were treated with IVIG induction dose followed by 2- to 3- monthly infusions were retrospectively identified. Annualized relapse rates (ARR) and Expanded Disability Status Scale (EDSS) pre- and post-IVIG were recorded. RESULTS: Median number of relapses and median ARR significantly reduced from 8.0 to 1.0 and 0.75 to 0.15 (p<0.05) respectively. Median EDSS of 6.5 remained the same. Median duration of treatment was 4.0 years. CONCLUSION: IVIG may be used to reduce the relapse frequency in patients with NMO/NMOSD.
Authors: Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob Journal: J Neurol Date: 2019-09-03 Impact factor: 4.849
Authors: Benedikt Grünewald; Jeffrey L Bennett; Klaus V Toyka; Claudia Sommer; Christian Geis Journal: Int J Mol Sci Date: 2016-08-26 Impact factor: 5.923